Taysha Posts $46.6M Q2 Loss, Completes Dosing in Pivotal TSHA-102 Trials, and Extends Cash Runway into 2H 2028
TSHA has more than doubled off its 52-week low of $2.685.
Summary
Taysha Gene Therapies reported a Q2 net loss of $46.6 million, completed dosing in its pivotal TSHA-102 trials for Rett syndrome, and ended the quarter with $455.4 million in cash — enough to fund operations into the second half of 2028 and through a potential BLA approval.
Key Events · Earnings and Guidance · TSHA
-
Q2 Net Loss Widens to $46.6M
Net loss reached $46.6M ($0.13/share) compared with $26.9M ($0.09/share) in Q2 2025, as R&D expenses climbed $18.5M to $38.6M for BLA-enabling manufacturing and clinical trials, while G&A rose $3.5M to $12.1M for commercial readiness.
-
Dosing Complete in Pivotal TSHA-102 Trials
Dosing is now complete in the overenrolled REVEAL pivotal trial (N=17) and the ASPIRE safety trial (N=4) for TSHA-102 in Rett syndrome. As of August 2026, TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across 33 patients.
-
Cash Runway Extended into 2H 2028
Cash and cash equivalents stood at $455.4M as of June 30, 2026, reflecting the $230M follow-on offering completed in June 2026. Management expects this to fund operations into the second half of 2028 and through potential BLA approval of TSHA-102.
-
Topline Data and FDA Feedback Expected 1H 2027
The 6-month interim analysis of the REVEAL pivotal trial, which may serve as the basis for a BLA submission, is expected in 1H 2027, along with FDA feedback on the BLA pathway. Completion of the BLA-enabling PPQ manufacturing campaign is expected in Q4 2026.
Analysis · TSHA · Life Sciences
A near-doubling of R&D spend to advance TSHA-102 toward a BLA drove Taysha's wider Q2 net loss. Dosing is now complete in both the pivotal REVEAL trial and the ASPIRE safety study, de-risking the clinical timeline ahead of topline data and FDA feedback expected in 1H 2027. The $455.4M cash position, strengthened by the recent $230M follow-on, funds operations through potential approval and removes near-term financing overhang. An expanded partnership with Catalent adds commercial manufacturing readiness. For this pre-commercial biotech, the 1H 2027 clinical readout stands as the binary event that will define its future.
At the time of this filing, TSHA was trading at $6.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $2.69 to $7.30. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.